Evaluation of Glycemic and Hepatic Markers in Patients with Non-Alcoholic  Fatty Liver Disease (NAFLD) Treated with Pioglitazone

Asia Firdous, Ghulam Ovais Qarni, Javeria Sarfraz, Muzamil Liaqat Ali, Arooj  Fatima, Waleed Arshad

Evaluation of Glycemic and Hepatic Markers in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD) Treated with Pioglitazone

Authors

Asia Firdous, Ghulam Ovais Qarni, Javeria Sarfraz, Muzamil Liaqat Ali, Arooj Fatima, Waleed Arshad

Keywords:

Pioglitazone, Non-Alcoholic Fatty Liver Disease, Glycemic Control

Abstract

Non-Alcoholic Fatty Liver Disease (NAFLD) is a prevalent metabolic disorder characterized byhepatic steatosis in the absence of significant alcohol consumption. Recent therapeutic strategieshave explored the efficacy of pioglitazone

References

Kablak-Ziembicka A, Przewlocki T. Clinical significance of carotid intima-media complex and carotid plaque assessment by ultrasound for the prediction of adverse cardiovascularevents in primary and secondary care patients. J Clin Med. 2021;10(20):4628. DOI: https://doi.org/10.3390/jcm10204628

Downloads

Published

2025-05-30

How to Cite

Asia Firdous, Ghulam Ovais Qarni, Javeria Sarfraz, Muzamil Liaqat Ali, Arooj Fatima, Waleed Arshad. (2025). Evaluation of Glycemic and Hepatic Markers in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD) Treated with Pioglitazone. International Journal of Pharmacy Research & Technology (IJPRT), 15(1), 1343–1349. Retrieved from https://www.ijprt.org/index.php/pub/article/view/578